KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Current Liabilities (2016 - 2025)

Sarepta Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $1.1 billion for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 49.69% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 49.69%, while the annual FY2025 figure was $1.1 billion, 49.69% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $1.1 billion at Sarepta Therapeutics, up from $921.4 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $1.1 billion in Q4 2025 and troughed at $364.7 million in Q1 2021.
  • A 5-year average of $612.5 million and a median of $604.3 million in 2022 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 61.45% in 2022 and later dropped 25.24% in 2023.
  • Year by year, Total Current Liabilities stood at $452.7 million in 2021, then soared by 36.86% to $619.6 million in 2022, then increased by 5.5% to $653.7 million in 2023, then rose by 11.94% to $731.7 million in 2024, then soared by 49.69% to $1.1 billion in 2025.
  • Business Quant data shows Total Current Liabilities for SRPT at $1.1 billion in Q4 2025, $921.4 million in Q3 2025, and $919.9 million in Q2 2025.